Managing COVID-19 post viral fatigue syndrome
Managing COVID-19 post viral fatigue syndrome, by Charles W Lapp and Joseph F John in Fatigue: Biomedicine, Health & Behavior, Feb 22, 2021 Article abstract: In online surveys, over 50%…
Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Clinical Trial Arena: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection, 7 January 2021 AIM ImmunoTech has dosed its first Covid-19 ‘long hauler’ patient in the…
Estimating prevalence, demographics & costs of ME/CFS using large scale medical claims data & Machine Learning (US)
Estimating prevalence, demographics and costs of ME/CFS using large scale medical claims data and machine learning, by Ashley Valdez, Elizabeth E. Hancock, Seyi Adebayo, David Kiernicki, Daniel Proskauer, John R….
Initiating care of a patient with ME/CFS
Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), by Charles W. Lapp in Front. Pediatr., [Published 23 January 2019] Article abstract: This paper introduces the primary…
Mast Cell Activation may underlie CFS
Medscape blog post, 13 March 2018, by Miriam Tucker: Mast Cell Activation may underlie ‘Chronic Fatigue Syndrome’ Mast cell activation syndrome (MCAS) may be an overlooked yet potentially treatable contributor…
Nausea and sickness: non-drug options
MEA blog post, 29 June 2016: Dr Charles Shepherd reports on two non-drug options for nausea and sickness in ME/CFS New guidance from the Royal College of Obstetricians and Gynaecologists…